Anlon Allotment Alert: Will Your PAN Reveal a Pharma Payday?

With the subscription window now closed, investors are eagerly awaiting the allotment results of Anlon Healthcare’s initial public offering. The IPO, which ran from August 26 to August 29, 2025, drew strong interest from retail investors and is now entering its final phase before listing. Here's a comprehensive breakdown of the allotment process, grey market premium trends, and what it all means for prospective shareholders.

1. Allotment Status: How and Where to Check

The basis of allotment for Anlon Healthcare IPO is scheduled to be finalized on Monday, September 1. Investors can check their allotment status online using their PAN, application number, or demat account details.

- Visit the BSE website and navigate to the IPO allotment section  
- Select ‘Equity’ under issue type and choose ‘Anlon Healthcare Ltd’ from the dropdown  
- Enter your PAN or application number and complete the captcha verification  
- Click ‘Search’ to view your allotment status  

Alternatively, investors can check via:

- Kfin Technologies portal at ipostatus.kfintech.com  
- NSE’s IPO allotment page after registering with PAN credentials  
- Their demat account or bank account to verify share credit or refund status  

2. Subscription Snapshot: Strong Retail Demand

The IPO was subscribed 7.12 times overall, with retail investors leading the charge.

- Retail quota was oversubscribed 47.26 times  
- Non-institutional investors (NII) subscribed 10.61 times  
- Qualified institutional buyers (QIB) saw a modest 1.07 times subscription  

This strong demand from retail participants reflects confidence in Anlon’s business model and growth potential, despite muted institutional enthusiasm.

3. Grey Market Premium: A Lukewarm Signal

As of August 30, the grey market premium (GMP) for Anlon Healthcare IPO stood at Rs 2 over the upper price band of Rs 91, indicating a listing estimate of Rs 93.

- This translates to a modest 2.20 percent premium, suggesting a flat or mildly positive listing  
- GMP trends are speculative and driven by market sentiment, not official indicators  
- Earlier GMP estimates had hovered around Rs 5, but recent dips reflect cautious investor mood  

4. IPO Details: Price Band, Lot Size, and Objectives

Anlon Healthcare offered 1.33 crore equity shares with a face value of Rs 10 each.

- Price band was set between Rs 86 and Rs 91 per share  
- Minimum lot size was 164 shares, requiring an investment of Rs 14,104 for retail applicants  
- The IPO aimed to raise Rs 121.03 crore  

Proceeds from the issue will be used for:

- Capital expenditure for manufacturing expansion  
- Repayment or prepayment of secured borrowings  
- Working capital requirements  
- General corporate purposes  

5. Company Profile: Pharma Precision with Global Reach

Founded in 2013, Anlon Healthcare Ltd. specializes in high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs).

- Its products are used in medicines, nutraceuticals, personal care, and veterinary applications  
- The company is one of the few domestic producers of loxoprofen sodium dihydrate, a key pain-relief compound  
- It operates a manufacturing facility in Rajkot, Gujarat, with an installed capacity of 400 MTPA and four in-house labs  
- Regulatory approvals from Brazil, China, and Japan enhance its export potential  

6. Listing Date and Market Outlook

Anlon Healthcare shares are set to be listed on both BSE and NSE on Wednesday, September 3.

- Market observers expect a cautious debut, with listing gains likely to be minimal  
- Analysts suggest watching post-listing performance closely, especially given the company’s niche product portfolio and export credentials  

While the GMP signals a subdued start, Anlon Healthcare’s fundamentals and strategic positioning in the pharma supply chain could offer long-term value. For now, all eyes are on the allotment results and the September 3 listing.

Sources: News18, ET Now, MSN Money, IPOwiz, NDTV Profit, Financial Express, Times Now Business